John G Ullman & Associates Inc. Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

John G Ullman & Associates Inc. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 32,664 shares of the medical equipment provider's stock, valued at approximately $3,975,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Zimmer Biomet by 19.0% during the first quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider's stock worth $2,954,843,000 after purchasing an additional 3,695,510 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its stake in shares of Zimmer Biomet by 92,041.0% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,841,898 shares of the medical equipment provider's stock valued at $234,842,000 after acquiring an additional 1,839,899 shares during the last quarter. Norges Bank bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $231,471,000. Morgan Stanley lifted its stake in shares of Zimmer Biomet by 80.5% in the 4th quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider's stock valued at $395,560,000 after acquiring an additional 1,384,068 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Zimmer Biomet by 657.0% in the 4th quarter. Victory Capital Management Inc. now owns 1,393,963 shares of the medical equipment provider's stock valued at $177,730,000 after acquiring an additional 1,209,827 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.95% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on ZBH. Royal Bank of Canada reissued an "outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 9th. Evercore ISI upped their target price on Zimmer Biomet from $125.00 to $130.00 and gave the stock an "in-line" rating in a report on Thursday, April 4th. Canaccord Genuity Group reiterated a "hold" rating and set a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. StockNews.com downgraded Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a research note on Monday, February 19th. Finally, Barclays upped their price target on Zimmer Biomet from $120.00 to $130.00 and gave the stock an "underweight" rating in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $139.39.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded up $0.10 during midday trading on Friday, hitting $119.43. 1,296,143 shares of the stock traded hands, compared to its average volume of 1,481,159. The firm has a 50-day moving average of $126.33 and a two-hundred day moving average of $119.16. The firm has a market capitalization of $24.54 billion, a P/E ratio of 24.42, a PEG ratio of 2.23 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion for the quarter, compared to analysts' expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company's revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.88 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet's payout ratio is 19.63%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.